

**BEST AVAILABLE COPY**100718-49  
6713-Dr. Ly-sch 196/129**AMENDMENTS TO THE CLAIMS****Claim 1 (currently amended)**

1. A method for the prophylaxis and treatment of rosacea and couperose which comprises applying to a patient in need thereof an effective amount of one compound or two or more compounds selected from the group consisting of NO-synthase inhibitors and salts thereof.

**Claim 2 (previously amended)**

2. The method of claim 1, wherein said compound or compounds are applied in the form of a cosmetic or dermatological topical preparation.

**Claim 3 (cancelled)****Claim 4 (previously amended)**

4. Method according to Claim 2, wherein the preparations comprise at least one antioxidant.

**Claim 5 (previously amended)**

5. Method according to Claim 2, wherein the preparations comprise at least one UVA filter, at least one UVB filter, at least one inorganic pigment or a combination of both.

**Claim 6 (previously amended)**

6. Method according to Claim 2, wherein the preparations comprise at least one antioxidant and at least one UVA filter, at least one UVB filter, at least one inorganic pigment or a combination thereof.

**Claim 7 (previously amended)**

7. Method according to Claim 1, wherein said one compound or two or more compounds is selected from the group of N<sup>G</sup>-monoalkyl-L-arginine, N<sup>G</sup>, N<sup>G</sup>-dialkyl-L-arginine, N<sup>G</sup>, N<sup>G</sup>-dialkyl-L-arginine and N<sup>G</sup>-nitro-L-arginine and derivatives thereof.

**Claim 8 (previously amended)**

8. Method according to Claim 2, wherein said compound or compounds are selected from the group consisting of N<sup>G</sup>-monoalkyl-L-arginine, N<sup>G</sup>, N<sup>G</sup>-dialkyl-L-arginine, N<sup>G</sup>, N<sup>G</sup>-dialkyl-L-arginine and N<sup>G</sup>-nitro-L-arginine and derivatives thereof.

**BEST AVAILABLE COPY**100718-49  
8713-Dr. Ly-sch 196/129**Claims 9 and 10 (cancelled)****Claim 11 (previously amended)**

11. Method according to Claim 8, wherein the preparations comprise at least one antioxidant.

**Claim 12 (previously amended)**

12. Method according to Claim 8, wherein the preparations comprise at least one UVA filter, at least one UVB filter, at least one inorganic pigment or a combination thereof.

**Claim 13 (previously amended)**

13. Method according to Claim 8, wherein the preparations comprise at least one antioxidant and at least one UVA filter, at least one UVB filter and/or at least one inorganic pigment or a combination thereof.

**Claim 14 (previously amended)**

14. Method of Claim 1, wherein said NO-synthase inhibitors contain an arginine radical.

**Claim 15 (previously amended)**

15. Method of Claim 14, wherein said compounds are applied in the form of cosmetic or dermatological topical preparations.

**Claims 16 and 17 (cancelled)****Claim 18 (previously added)**

18. The method according to claim 1, which is for the treatment of rosacea and couperose.

**Claim 19 (currently amended)**

19. A method for the prophylaxis and treatment of rosacea and couperose which comprises applying to a patient in need thereof an effective amount of an NO-synthase inhibitor or salt thereof which is selected from the group consisting of N<sup>G</sup>-monoethyl-L-arginine monoacetate, 2-Iminobiotin, L-N<sup>G</sup>-(1-iminoethyl)-ornithine, S-Methylisothiourea sulphate, S-Methyl-L-thiocitrulline, L-N<sup>G</sup>-(1-iminoethyl)lysine, 7-Nitroindazole, S,S'-1,3-Phenylene-bis(1,2-ethanediyl)-bis-isothiourea, L-Thiocitrulline, alpha-N-acetyl-N<sup>G</sup>-nitro-L-arginine methyl ester and salts thereof.

**Claim 20 (previously amended)**

**BEST AVAILABLE COPY**100718-49  
6713-Dr. Ly-sch 196/129

20. The method of claim 19, wherein said NO-synthase inhibitor is selected from the group consisting of 2-Iminobiotin, L-N<sup>5</sup>-(1-iminoethyl)-ornithine, S-Methylisothiourea sulphate, S-Methyl-L-thiocitrulline, L-N<sup>G</sup>-(1-iminoethyl)lysine, 7-Nitroindazole, S,S'-1,3-Phenylene-bis(1,2-ethanediyl)-bis-isothiourea, L-Thiocitrulline, and salts thereof.

## Claim 21 (previously amended)

21. The method of claim 20, wherein said NO-synthase inhibitor or salt thereof further comprises L<sup>G</sup>-Nitro-L-arginine methyl ester hydrochloride.

## Claim 22 (previously added)

22. The method of claim 20 or 21, wherein the amount of NO-synthase inhibitor is from 0.001% to 20% by weight based on the total weight of the preparation.

## Claim 23 (previously added)

23. The method of claim 22, wherein the amount of NO-synthase inhibitor is from 0.01% to 10% by weight based on the total weight of the preparation.

## Claim 24 (previously added)

24. The method of claim 23, wherein the amount of NO-synthase inhibitor is from 0.1 to 5% by weight based on the total weight of the preparation.

## Claims 25-27 (cancelled)